论文部分内容阅读
目的 探讨达昔单抗 (Dac ,赛尼哌 )在预防肾移植术后急性排斥反应中的作用。 方法 2 92例肾移植患者随机分为达昔单抗治疗组 (94例 )与对照组 (198)例 ,分析 2组移植肾功能、急性排斥反应发生情况以及外周血T细胞亚群的变化。 结果 术后 1、6及 12个月时达昔单抗组移植肾功能优于对照组 ,术后 12个月时 2组SCr浓度分别为 (133.2± 4 6 .8)和 (16 5 .7± 5 5 .2 ) μmol/L ,差异有统计学意义 (P <0 .0 5 )。术后 6个月时达昔单抗组急性排斥反应发生率为 2 3.4 % ,对照组为38.4 % ,差异有统计学意义 (P <0 .0 5 ) ;术后 2组CD+ 3 与CD+ 4 表达均下降 ,但差异无统计学意义 (P>0 .0 5 )。 结论 达昔单抗可以降低急性排斥反应发生率 ,改善移植肾功能 ,对T细胞亚群无明显影响。
Objective To investigate the effect of daclizumab (dac, daclizumab) in preventing acute rejection after renal transplantation. Methods Totally 92 patients with renal allograft were randomly divided into two groups: control group (n = 94) and control group (n = 98). The renal function, acute rejection and T cell subsets in peripheral blood were analyzed. Results The renal allograft function was better in the control group at 1, 6 and 12 months after operation. The SCr concentrations in the two groups at 12 months after operation were (133.2 ± 46.8) and (16.57 ± 5 5 .2) μmol / L, the difference was statistically significant (P <0. 05). The incidence of acute rejection in the control group was 23.4% at 6 months after operation and 38.4% in the control group (P <0.05). The postoperative CD + 3 and CD + 4 levels Expression decreased, but the difference was not statistically significant (P> 0.05). CONCLUSION: Herceptin can reduce the incidence of acute rejection, improve renal function and have no significant effect on T cell subsets.